HHS officials say that fully vaccinated individuals do not need to get a booster shot; FDA issues a warning on link between the Johnson & Johnson vaccine and a rare neurological condition; California counties sue pesticide manufacturer over widely used bug killer that may cause brain damage in children and fetuses.
HHS officials said after a meeting with COVID-19 vaccine manufacturer Pfizer yesterday that fully vaccinated individuals do not need to get a booster shot amid the spread of more contagious variants across the United States. As reported by Reuters, agency officials said that data on current vaccine dosage efficacy will determine whether a booster shot would be needed in the future. Notably, high-risk individuals, such as elderly nursing home residents and immunocompromised people, were cited as a group who may potentially require the booster shots, but so far no data have suggested a significant waning of efficacy or an increase in COVID-19 infection in those who are fully vaccinated.
Yesterday, the FDA issued a warning that the COVID-19 vaccine manufactured by Johnson & Johnson (J&J) can lead to an increased risk of a rare neurological condition known as Guillain-Barré syndrome, which occurs when the immune system damages nerve cells, causing muscle weakness and occasional paralysis. According to The New York Times, the risk of developing the condition is low, with approximately 100 suspected cases identified so far, but the risk appears to be 3 to 5 times higher among those who received the J&J vaccine. Moreover, the FDA said that available evidence suggests an association between the vaccine and the condition, but there remains insufficient evidence to establish a causal link.
As reported by the Associated Press, a California lawsuit issued yesterday is seeking damages from Dow Chemical and its affiliated Corteva Inc over its pesticide chlorpyrifos, a widely used bug killer that may cause brain damage in fetuses and children. Having already been banned for sale and use in California, lawyers estimate that at least 100,000 homes in the state may need to dispose of most of their belongings due to potential contamination. From 1974 to 2017, 61 million pounds of the pesticide were applied in the 4 California counties where the lawsuits were filed: Fresno, Kings, Madera, and Tulare.
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
AHN’s Center for Inclusion Health Personalizing Equitable Care Delivery for Marginalized Communities
February 28th 2023On this episode of Managed Care Cast, we speak with Elizabeth Cuevas, MD, division chief of Allegheny Health Network’s (AHN) Center for Inclusion Health, on prevalent health inequities facing marginalized communities and strategies to identify and address these issues.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More